loss(3,430,838)(813,499)Interest and financing expenses (69,697)(124,375)Interest income145,374131,483Other income8,61111,309Loss on disposal and write down of equipment(7,704)(687,095)Loss before income taxes and non-controlling interests(3,354,254)(1,482,177)Income tax
recovery (expense)(310,422)269,479Consolidated net loss(3,664,676)(1,212,698)Loss attributable to non-controlling interests869,720905,388Net loss attributable to stockholders$
(2,794,956)
$
(307,310)Net loss$
(3,664,676)
$
(1,212,698)Other comprehensive incomeForeign currency translation adjustment839,5678,723Total comprehensive loss(2,825,109)(1,203,975)Comprehensive loss attributable to non-controlling interests 728,475903,911Comprehensive loss attributable to stockholders$
(2,096,634)
$
(300,064)Loss per share– basic and diluted
$
0.05
$
0.01Weighted average number of shares of common stock outstanding8211; Basic and Diluted54,444,07749,873,422SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Statements of Cash FlowsThree months ended March 31, 2011 and 2010(Unaudited)(Expressed in U.S. Dollars)Three months endedMarch 3120112010Cash flows from (used in) operating activities Net loss
$
(3,664,676)
$
(1,212,698) Adjustments to reconcile net income to net cash provided by operating activities: - deferred income taxes310,422692,520 - stock-based compensation32,662103,664- inventory provision-16,206 - write-down of equipment and loss on disposal7,704687,09
'/>"/>
SOURCE Sinovac Biotech Ltd. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine technology :1.
Sinovac Presents at Two Investor Conferences in May 20112.
Sinovac Files Annual Report on Form 20-F3.
Sinovac Participates in UBS Greater China Healthcare Corporate Day4.
Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group5.
Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)6.
Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range7.
Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market8.
Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine9.
Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations10.
Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens11.
Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)